Manchester Metropolitan University. (2026) Greater Manchester: testing and research on emergent and new drugs: 2025-26 monitoring cycle. Full report. Manchester: Greater Manchester Combined Authority.
| Preview | Title | Contact |
|---|---|---|
|
PDF (Greater Manchester: testing and research 2025-26 monitoring cycle full report)
3MB | |
|
PDF (The Greater Manchester street drug survey 2025/26)
4MB |
External website: https://gmtrends.mmu.ac.uk/
GM TRENDS aims to gather up-to-date information on changing and emerging substance use trends in Greater Manchester. The findings inform the Greater Manchester Local Drugs Information System and are used to provide recommendations to local authorities regarding the development and delivery of services for substance users. The identification of emerging trends helps to ensure that commissioners, service providers and local professionals who come into contact with people who use drugs (PWUDs) are best placed to understand their local needs and the services required. The identification of at-risk groups in our communities is important to ensure that appropriate needs assessment and support are provided. This should include the development of appropriate harm reduction advice, staff training and awareness raising...
_____________________________________
The GM street drug survey report draws on three sources: an online survey of 212 professionals, 85 in depth interviews with professionals, and interviews with 48 individuals who use ‘street drugs’. Eligibility criteria required participants to be currently using at least one of the following substances: heroin, crack cocaine, synthetic cannabinoids (‘Spice’), benzodiazepines, or pregabalin. The aim was to engage approximately four participants from each of the ten Greater Manchester areas. To ensure we captured the perspectives of both people in treatment and those not engaged with treatment services, recruitment was facilitated through a mix of drug treatment providers, homeless drop-in centres, homelessness charities, and supported accommodation. Thirty-nine men and nine women ranging in age from 22 to 58 were interviewed from nine Greater Manchester areas...
A Substance use and dependence > Prevalence > Substance use behaviour > Alcohol consumption
B Substances > Cannabis / Marijuana
B Substances > Alcohol
B Substances > Tobacco (cigarette smoking)
B Substances > Tobacco (cigarette smoking) > Nicotine product (e-cigarette / vaping / heated)
B Substances > Cannabis product / compounds (Plant-derived cannabinoids) > Cannabinol / Cannabidiol (CBD oil)
B Substances > Hallucinogens / Psychedelics > LSD (Lysergic acid diethylamide)
B Substances > Hallucinogens / Psychedelics > Mushrooms (psilocybin / Amanita muscaria /Psilocybe)
B Substances > Inhalants and solvents > Nitrous oxide (laughing gas)
B Substances > CNS stimulants > Amphetamines
B Substances > CNS stimulants > Methamphetamine
B Substances > CNS stimulants > MDMA / Ecstasy
B Substances > Cocaine
B Substances > Opioids (opiates)
B Substances > Opioids (opiates) > Heroin (diacetylmorphine / diamorphine)
B Substances > Opioids (opiates) > Opioid product
B Substances > Opioids (opiates) > Opioid product > Codeine or tramadol
B Substances > Opioids (opiates) > Opioid product > Naloxone
B Substances > Opioids (opiates) > Opioid product > Buprenorphine / Suboxone
B Substances > Opioids (opiates) > Opioid product > Methadone
B Substances > Steroids / performance image enhancing
B Substances > New (novel) psychoactive substances > Aminoindanes / Arylalkylamines / Arylcyclohexylamines > Ketamine
B Substances > New (novel) psychoactive substances > Benzodiazepines
B Substances > New (novel) psychoactive substances > Plants and extracts > Kratom (Mitragyna speciosa)
B Substances > New (novel) psychoactive substances > NPS cannabinoids > Synthetic cannabinoids (Spice)
B Substances > New (novel) psychoactive substances > NPS cannabinoids > Semi-synthetic cannabinoids (HHC)
B Substances > New (novel) psychoactive substances > Synthetic cathinones > Mephedrone
B Substances > New (novel) psychoactive substances > Synthetic opioids
B Substances > New (novel) psychoactive substances > Synthetic opioids > Fentanyl, Fentanils
B Substances > New (novel) psychoactive substances > Synthetic opioids > Benzimidazole, Nitazenes, Brorphine
B Substances > New (novel) psychoactive substances > Other novel substances > Gabapentinoids GABA (Pregabalin / Gabapentin)
B Substances > New (novel) psychoactive substances > Other novel substances > GHB / GBL (Gamma hydroxybutyric / Gamma butyrolactone)
B Substances > New (novel) psychoactive substances > Other novel substances > Xylazine, detomidine, medetomidine
B Substances > New (novel) psychoactive substances > Other novel substances > Zopiclone, eszopiclone, zaleplon and zolpidem
B Substances > New (novel) psychoactive substances > Other novel substances > Amyl nitrites (poppers)
E Concepts in biomedical areas > Medical substance > Prescription drug (medicine / medication)
E Concepts in biomedical areas > Medical substance > Medical / medicinal cannabis
G Health and disease > Substance use disorder (addiction) > Drug use disorder > Drug intoxication > Poisoning (overdose)
HA Screening, identification, and diagnostic method > Physical / medical screening, assessment and diagnostic method
J Health care, prevention, harm reduction and treatment > Risk and needs assessment > Risk assessment > Early warning monitoring system
J Health care, prevention, harm reduction and treatment > Identification and screening > Identification and screening for substance use
J Health care, prevention, harm reduction and treatment > Identification and screening > Identification and screening for substance use > Drug checking / testing service
VA Geographic area > Europe > United Kingdom or Great Britain > England
Repository Staff Only: item control page